International Journal of COPD · 2014 · 10 citations · 22 references
PharmacyClinical SciencesPharmacotherapyPulmonary Function TestingPulmonologyRespiratory PharmacotherapyBronchodilator TherapyChronic Obstructive Pulmonary DiseaseChronic Obstructive Pulmonary Disease PharmacotherapyInhalation Dosage FormsInhalation TherapyPulmonary Function AssessmentChronic Obstructive Pulmonary Disease AssessmentChronic Obstructive Pulmonary Disease BronchodilationChronic Obstructive Pulmonary Disease Exacerbation TreatmentCopd Symptom ManagementDyspnea MeasurementDyspnea Symptom RatingForced Vital Capacity ChangeLong-acting Bronchodilator Therapy
BACKGROUND: Indacaterol is a novel, once-daily, inhaled, long-acting b2-agonist for patients with chronic obstructive pulmonary disease (COPD). The study objective was to evaluate the efficacy of indacaterol on quality of life and pulmonary function in patients with COPD in a real-world setting, and also to evaluate its inhaler device (Breezhaler®), which is important for both adherence and management. METHODS: Twenty-eight outpatients with COPD were treated with indacaterol (150 μg once daily for 8 weeks), and the effects on pulmonary function were evaluated using a questionnaire survey with the modified Medical Research Council (mMRC) dyspnea scale and COPD assessment test (CAT) before and after treatment. Similar investigations were also performed separately among different baseline medications. Moreover, original questionnaire surveys for indacaterol and its device were performed. RESULTS: Overall, mMRC dyspnea scale and CAT scores significantly improved (1.96±1.04 to 1.57±1.07 and 17.39±8.23 to 12.82±8.42, respectively; P<0.05). Significant improvements in forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1) were also observed on pulmonary function tests (2.91±0.66 L to 3.07±0.65 L and 1.46±0.60 L to 1.58±0.59 L, respectively; P<0.05). Replacement therapy from salmeterol to indacaterol significantly improved mMRC and FVC values, but did not significantly improve CAT scores or other pulmonary functions. Add-on therapy with indacaterol significantly improved mMRC score, CAT score, FVC, and FEV1, regardless of whether tiotropium was used as a baseline treatment. All subjects in a questionnaire survey found the inhaler device easy to use. There were no serious adverse events leading to treatment discontinuation. CONCLUSION: Indacaterol is thought to be effective and well tolerated as a bronchodilator for the management of COPD. Treatment with indacaterol in addition to a long-acting muscarinic antagonist was also useful.
22
Projections of Global Mortality and Burden of Disease from 2002 to 2030
Colin Mathers, Dejan Lončar · PLoS Medicine · 2006 · 11.5K citations · Full text
Chronic obstructive pulmonary disease: current burden and future projections
Alan D López, Kenji Shibuya, Chalapati Rao et al. · European Respiratory Journal · 2006 · 1.3K citations · Full text
Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD
Claus Vogelmeier, Bettina Hederer, Thomas Glaab et al. · New England Journal of Medicine · 2011 · 681 citations · Full text
Adherence to inhaled therapy, mortality and hospital admission in COPD
Jørgen Vestbo, Julie A. Anderson, Peter M.A. Calverley et al. · Thorax · 2009 · 524 citations · Full text
Medicine, Oncology, Pharmacology +14